Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Carcinoma, Large Cell × brigatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lung Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Large Cell 1 Carcinoma 1 Adenocarcinoma 1 ALK+ Advanced NSCLC 1

Interventions

figitumumab 2 vandetanib 1 cemiplimab 1 brigatinib 1 alpha-2'-deoxythioguanosine 1 Vinorelbine 1 Paclitaxel 1 Gemcitabine 1 Erlotinib Hydrochloride 1 Docetaxel 1 Crizotinib 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02737501 2021-08-20

ALTA-1L

Takeda

Phase 3 Completed

275 enrolled 23 charts 2 FDA

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Carcinoma, Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡